A1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 939-947

  Canales, Norma Angélica Galicia ^a   Marina, Vicente Madrid ^a   Castro, Jorge Salmerón ^b   Jiménez, Alfredo Antúnez ^b   Mendoza Hernández, Guillermo ^c   McCarron, Elizabeth Langley ^d   Roman, Margarita Bahena ^a   Castro Romero, Julieta Ivone ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b Epidemiology and Health Services Research Unit National Institute of Social Security   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

A1BG; Cervical cancer; CIN III; Complement C3; HPV

Indexed keywords

APOLIPOPROTEIN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; GLYCOPROTEIN IB ALPHA; HAPTOGLOBIN; VIRUS DNA;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CERVICAL INTRAEPITHELIAL NEOPLASIA III; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DENSITOMETRY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PILOT STUDY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; WESTERN BLOTTING;

EID: 84902315697     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2195     Document Type: Article

References (62)

1. Weiderpass E and Labrèche F: Malignant tumors of the female reproductive system. Saf Health Work 3: 166-180, 2012.
2. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
4. Bruni L, Barrionuevo-Rosas L, Serrano B, et al: Human Papillomavirus and Related Diseases Report: Mexico. http://www.hpvcentre.net/statistics/reports/MEX.pdf. Accessed March 17, 2014.
5. Richart RM: Cervical intraepithelial neoplasia. Pathol Annu 8: 30-28, 1973.
6. Richart RM: A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol 75: 131-133, 1990.
7. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119, 2002.
8. Syrjänen K: Histology, classification and natural history of cervical intraepithelial neoplasia (CIN). CME J Gynecol Oncol 14: 4-21, 2009.
9. Correa P: A human model of gastric carcinogenesis. Cancer Res 48: 3554-3560, 1988.
10. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, et al: DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 97: 908-915, 2005.
11. Wright TC Jr: Cervical cancer screening in the 21st century: is it time to retire the Pap smear? Clin Obstet Gynecol 50: 313-323, 2007.
12. Burd E: Human papillomavirus and cervical cancer. Clin Microbiol Rev 16: 1-17, 2003.
13. Snijders PJ, Heideman DA and Meijer CJ: Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 118: 520-528, 2010.
14. Grubisić G, Klarić P, Jokanović L, et al: Diagnostic approach for precancerous and early invasive cancerous lesions of the uterine cervix. Coll Antropol 33: 1431-1436, 2009.
15. Cho W: Proteomics technologies and challenges. Genomics Proteomics Bioinformatics 5: 77-85, 2007.
16. Breuer EK and Murph MM: The role of proteomics in the diagnosis and treatment of women's cancers: current trends in technology and future opportunities. Int J Proteomics 2011: 1-17, 2011.
17. Veenstra TD, Conrads TP, Hood BL, et al: Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 4: 409-418, 2005.
18. Xu X and Veenstra TD: Analysis of biofluids for biomarker research. Proteomics Clin 2: 1403-1412, 2008.
19. Abdul-Rahman PS, Lim BK and Hashim OH: Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods. Electrophoresis 28: 1989-1996, 2007.
20. Barba de la Rosa AP, Lugo-Melchor OY, Briones-Cerecero EP, Chagolla-López A, de León-Rodríguez A, Santos L, et al: Analysis of human serum from women affected by cervical lesions. J Exp Ther Oncol 7: 65-72, 2008.
21. Matthews R, Azuero A, Asmellash S, et al: Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepitelial neoplasia may differ by race. Inter J Womens Health 3: 185-192, 2011.
22. Guo X, Abliz G, Reyimu H, Zhao F, Kadeer N, Matsidik R, et al: The association of a distinct plasma proteomic profile with the cervical high-grade squamous intraepithelial lesion of Uyghur women: a 2D liquid-phase chromatography/mass spectrometry study. Biomarkers 17: 352-361, 2012.
23. Piyathilake CJ, Oelschlager DK, Meleth S, Partridge EE and Grizzle WE: Plasma protein profiles differ between women diagnosed with cervical intraepithelial neoplasia (cin) 1 and 3. Cancer Inform 2: 345-349, 2007.
24. Jeong DH, Kim HK, Prince AE, Lee DS, Kim YN, Han J and Kim KT: Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol 19: 173-180, 2008.
25. Looj ML, Karsani SA, Rahman MA, et al: Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma. J Biosci 34: 917-925, 2009.
26. Ono A, Kumai T, Koizumi H, et al: Overexpression of heat shock protein 27 in squamous cell carcinoma of the uterine cervix: a proteomic analysis using archival formalin-fixed, paraffin-embedded tissues. Hum Pathol 40: 41-49, 2009.
27. Zhu X, Lv J, Yu L, et al: Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol 112: 248-256, 2009.
28. Liu C, Pan C, Shen J, et al: Discrimination analysis of mass spectrometry proteomics for cervical detection. Med Oncol 28 (Suppl 1): S553-S559, 2011.
29. Fukushima C, Murakami A, Yoshitomi K, Sueoka K, Nawata S, Nakamura K and Sugino N: Comparative proteomic profiling in squamous cell carcinoma of the uterine cervix. Proteomics Clin Appl 5: 133-140, 2011.
30. Uleberg KE, Munk AC, Skaland I, Furlan C, van Diermen B, Gudlaugsson E, et al: A protein profile study to discriminate CIN lesions from normal cervical epithelium. Cell Oncol (Dordr) 34: 443-450, 2011.
31. Uleberg KE, Munk AC, Brede C, Gudlaugsson E, van Diermen B, Skaland I, et al: Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies. Proteome Sci 9: 36, 2011.
32. Pinto A, Crum C and Hirsch M: Molecular markers of early cervical neoplasia. Diagn Histopathology (Oxf) 16: 445-454, 2010.
33. Galgano MT, Castle PE, Atkins KA, et al: Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 34: 1077-1087, 2010.
34. Martin C and O'Leary JJ: Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 25: 605-615, 2011.
35. Anderson NL, Esquer-Blasco R, Hofmann JP and Anderson NG: A two-dimensional gel database of rat liver proteins useful in gene regulation and drug effects studies. Electrophoresis 12: 907-930, 1991.
36. Welinder C and Ekblad L: Coomassie staining as loading control in Western blot analysis. J Proteome Res 10: 1416-1419, 2011.
37. Lörincz A: Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 22: 629-636, 1996.
38. Yoshikawa H, Kawana K, Kitagawa K, et al: Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 82: 524-531, 1991.
39. Mishra A and Verma M: Cancer biomarkers: are we ready for the prime time? Cancers (Basel) 2: 190-208, 2010.
40. Gutman S and Kessler LG: The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 6: 565-571, 2006.
41. de Visser KE, Korets LV and Coussens LM: Early neoplastic progression is complement independent. Neoplasia 6: 768-776, 2004.
42. Pio R: Control of complement activation by cancer cells and its implications in antibody-mediated cancer immunotherapy. Revisión Inmunología 25: 173-87, 2006 (In Spanish).
43. Bjørge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE and Meri S: Ascitic complement system in ovarian cancer. Br J Cancer 92: 895-905, 2005.
44. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, et al: Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6: 2865-2873, 2006.
45. Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, et al: Biomarker identification in human pancreatic cancer sera. Pancreas 36: 61-69, 2008.
46. Xu G, Hou CR, Jiang HW, Xiang CQ, et al: Serum protein profiling to identify biomarkers for small renal cell carcinoma. Indian J Biochem Biophys 47: 211-218, 2010.
47. Pulay A, Füst G and Csömör A: Serum complement levels in patients with cancer of the uterine cervix before and after radiation therapy. Neoplasma 27: 211-216, 1980.
48. Ornellas P, Ornellas AA, Chinello C, Gianazza E, Mainini V, Cazzaniga M, et al: Down regulation of C3 and C4A/B complement factor fragments in plasma from patients with squamous cell carcinoma of the penis. Int Braz J Urol 38: 739-749, 2012.
49. Alfonso L, Moyses N, Alves G, Ornellas AA, Passos MR, do Oliveira LH and Cavalcanti SM: Prevalence of human papillomavirus and Epstein-Barr virus DNA in penile cancer cases from Brazil. Mem Inst Oswaldo Cruz 107: 18-23, 2012.
50. Campo MS, Graham SV, Cortese MS, Ashrafi GH, Araibi EH, Dornan ES, et al: HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407: 137-142, 2010.
51. Rutkowski MJ, Sughurue ME, Kane AJ, Mills SA and Parsa AT: Cancer and the complement cascade. Mol Cancer Res 8: 1453-1465, 2010.
52. Pakharukova NA, Pastushkova LKH, Moshkovskiǐ SA and Larina IM: Variability of healthy human proteome. Biomed Khim 58: 514-529, 2012 (In Russian).
53. Ishioka N, Takahashi N and Putnam FW: Amino acid sequence of human plasma alpha 1B-glycoprotein: homology to the immunoglobulin supergene family. Proc Natl Acad Sci. USA 83: 2363-2367, 1986.
54. Piyaphanee N, Ma Q, Kremen O, Czech K, Greis K, Mitsnefes M, et al: Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin Appl 5: 334-342, 2011.
55. Huang HL, Stasyk T, Morandell S, Dieplinger H, Falkensammer G, Griesmacher A, et al: Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and date validation by routine clinical assays. Electrophoresis 27: 1641-1650, 2006.
56. Weinberg ED: The role of iron in cancer. Eur J Cancer Prev 5: 19-36, 1996.
57. Thadikkaran L, Siegenthaler MA, Crettaz D, et al: Recent advances in blood-related proteomics. Proteomics 5: 3019-3034, 2005.
58. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, et al: Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 131: 911-923, 2012.
59. Jiang JT, Xu N, Zhang XY, Wu CP: Lipids changes in liver cancer. J Zhejiang Univ Sci B 8: 398-409, 2007 (In Chinese).
60. Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, et al: A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 3: 601-609, 2003.
61. Cohen M, Yossef R, Erez T, Kugel A, Welt M, Karpasas MM, et al: Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. Plos One 6: e14540, 2011.
62. Pio R, Ajona D and Lambris JD: Complement inhibition in cancer therapy. Semin Immunol 25: 54-64, 2013.